AOBO Featured in Steve Crowley's American Scene National Financial Talk-Radio Program

AOBO Featured in Steve Crowley's American Scene National Financial Talk-Radio Program

HONG KONG, April 20 /PRNewswire-FirstCall/ -- American Oriental Bioengineering Inc. (BULLETIN BOARD: AOBO) , a leading Chinese company, which produces and distributes a broad range of plant-based pharmaceutical and nutraceutical products, today announced that it will be featured in the Investor's Showcase on "Steve Crowley's American Scene" national financial talk-radio program. This special interview, which will be broadcast nationally via satellite via affiliates of the Business Talk Radio Network, will air on Thursday morning, April 20th at 9:23AM EDT and 6:23AM PDT.

AOBO debuted on the Investors' Showcase segment on April 13th.

Chairman and CEO Tony (Shujun) Liu will be interviewed on this program together with Company spokesperson, Hong Zhu, who acts as the translator for Mr. Liu, who speaks Chinese.

This special radio broadcast will originate from the American Stock Exchange in New York City and the entire program airs from 9AM to 11AM EDT. The focus of the interview will be the Company's growing and positive fundamentals, its products, and its recent press release that summarized the financial results for fiscal year 2004.

American Scene is hosted by Steve Crowley who is the former Money Editor of ABC-TV's "Good Morning America." Mr. Crowley is also a CPA, and the author of MONEY FOR LIFE, published by Simon & Schuster. American Scene has been on the air since June 1990, and regularly features major financial experts plus CEOs of smaller companies with high growth rates.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a leading Chinese developer and distributor of plant based pharmaceutical and nutriceutical products using natural plants and organic soybeans as raw materials.

The company has two product lines with over 100 products. The first is plant based pharmaceuticals including Shuanghuanglian Lyophilize Powder Injectable, and Cease-Enuresis Soft Gel. The second is nutraceuticals, including a series of soy protein peptide products and health supplements. These products can be delivered in forms of tablets, capsules, powder, and oral liquids.

American Oriental Bioengineering, Inc.'s product offering is based on three proprietary technologies, creating a unique process to extract soybean peptide more efficiently than using traditional techniques. Cease-Enuresis Soft Gel is the only China SFDA-approved first grade prescription natural plant medicine to treat bed-wetting and incontinence. Shuanghuanglian Lyophilize Powder Injectable is one of the only two Chinese government approved huangqin etc. herbs based anti-viral injectables in China. The Company is a leading producer of products in both the nutraceutical and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com/ .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All readers are encouraged to review the 8-K to be filed in connection with the acquisition discussed above, which outlines risk factors including debt obligations, deal terms and other relevant items. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the companies, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the companies disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact: America Oriental Bioengineering Inc. Lily Li, 917-838-0689 (U.S.) Hong Zhu (212) 786-7566 +86-451-86688139 (China) aobo@bioaobo.com

Investors: Ed Lewis CEOcast, Inc. for American Oriental Bioengineering 212-732-4300 elewis@ceocast.com

Source: American Oriental Bioengineering Inc.

CONTACT: America Oriental Bioengineering Inc.: Lily Li, 917-838-0689 (U.S.), Hong Zhu +1-212-786-7566, or +86-451-86688139 (China), aobo@bioaobo.com; Investors: Ed Lewis, CEOcast, Inc. for American Oriental Bioengineering, +1-212-732-4300, elewis@ceocast.com

Web site: http://www.bioaobo.com/

------- Profile: Ent